Eli Lilly faces more claims over diabetes treatment

A French company has brought additional claims of US$200 million against US pharmaceuticals giant Eli Lilly in an ICC arbitration begun last year over a collaborative research project to develop an insulin treatment for diabetes.

Unlock unlimited access to all Global Arbitration Review content